NASDAQ:ONC BeOne Medicines Q4 2024 Earnings Report $264.48 +4.21 (+1.62%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$264.53 +0.05 (+0.02%) As of 06/12/2026 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast BeOne Medicines EPS ResultsActual EPS-$1.43Consensus EPS -$0.88Beat/MissMissed by -$0.55One Year Ago EPSN/ABeOne Medicines Revenue ResultsActual Revenue$1.13 billionExpected Revenue$1.09 billionBeat/MissBeat by +$40.85 millionYoY Revenue GrowthN/ABeOne Medicines Announcement DetailsQuarterQ4 2024Date2/27/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile BeOne Medicines Earnings HeadlinesWolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)June 13 at 5:48 AM | theglobeandmail.comBeOne highlights phase 3 BRUKINSA data in older CLL patients and advances leadership position in BTK inhibitors (ONC)June 13 at 5:48 AM | msn.comThis Could Be the Biggest Monetary Shift in 50 YearsTucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold reserves from $42 per ounce to today's market value - a potential 107x shift. President Trump has signaled interest in returning the dollar to commodity-backed foundations. More than 60 million Americans can move a portion of their savings into physical gold, tax-free and penalty-free, before any policy change is announced. The 2026 Gold Guide explains exactly how to position your 401(k) or IRA outside the dollar-denominated system.June 14 at 1:00 AM | Americas Gold Company (Ad)John Oyler Sells 4,940 Shares of BeOne Medicines (NASDAQ:ONC) StockJune 12 at 4:29 AM | americanbankingnews.comBeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA BenefitJune 11 at 7:24 AM | businesswire.comBeOne Medicines (ONC) Valuation Check After ASCO 2026 Solid Tumor UpdatesJune 5, 2026 | finance.yahoo.comSee More BeOne Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email. Email Address About BeOne MedicinesBeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.View BeOne Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationWhy Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors EarsThis Energy Stock Has Quietly Soared 130% in a Year Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
